Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent advances on FXR-targeting therapeutics
Katrin Panzitt, Gernot Zollner, Hanns‐Ulrich Marschall, et al.
Molecular and Cellular Endocrinology (2022) Vol. 552, pp. 111678-111678
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

Bile acids as modulators of gut microbiota composition and function
Anaïs Larabi, Hugo L. P. Masson, Andreas J. Bäumler
Gut Microbes (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 130
Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications
Jie Fang, Chen-Huan Yu, Xuejian Li, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 95
Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets
Joshua S. Fleishman, Sunil Kumar
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 56
FXR agonists in NASH treatment
Luciano Adorini, Michael Trauner
Journal of Hepatology (2023) Vol. 79, Iss. 5, pp. 1317-1331
Open Access | Times Cited: 46
Gut-liver axis: Pathophysiological concepts and medical perspective in chronic liver diseases
Susana Rodrigues, Van der Merwe, Aleksander Krag, et al.
Seminars in Immunology (2024) Vol. 71, pp. 101859-101859
Open Access | Times Cited: 15
The Gut–Vascular Barrier as a New Protagonist in Intestinal and Extraintestinal Diseases
Natalia Di Tommaso, Francesco Santopaolo, Antonio Gasbarrini, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1470-1470
Open Access | Times Cited: 30
Collaborative Metabolism: Gut Microbes Play a Key Role in Canine and Feline Bile Acid Metabolism
John C. Rowe, Jenessa A. Winston
Veterinary Sciences (2024) Vol. 11, Iss. 2, pp. 94-94
Open Access | Times Cited: 10
Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics
Serena Porcari, William G. Fusco, Igor Spivak, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 5, pp. 460-475
Closed Access | Times Cited: 8
Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling
Agostino Di Ciaula, Leonilde Bonfrate, Jacek Baj, et al.
Nutrients (2022) Vol. 14, Iss. 23, pp. 4950-4950
Open Access | Times Cited: 31
360-Degree Perspectives on Obesity
Magdalena Cuciureanu, Cătălin-Cezar Caratașu, Levon Gabrielian, et al.
Medicina (2023) Vol. 59, Iss. 6, pp. 1119-1119
Open Access | Times Cited: 20
Loss of renal tubular G9a benefits acute kidney injury by lowering focal lipid accumulation via CES1
Dong Yang, Yu Fan, Mingrui Xiong, et al.
EMBO Reports (2023) Vol. 24, Iss. 6
Closed Access | Times Cited: 16
Bile salt signaling and bile salt-based therapies in cardiometabolic disease
Claire C.J. Groenen, Thuc-Anh Nguyen, Coen C. Paulusma, et al.
Clinical Science (2024) Vol. 138, Iss. 1, pp. 1-21
Open Access | Times Cited: 6
Regulating bile acids signaling for NAFLD: molecular insights and novel therapeutic interventions
Meilin Wei, Wei Tu, Genhua Huang
Frontiers in Microbiology (2024) Vol. 15
Open Access | Times Cited: 6
Farnesoid X receptor regulates CYP1A1 and CYP1B1 and estradiol metabolism in mouse and human cell lines
Chanjuan Chen, Pei Lin, Zhen Wu, et al.
Chemico-Biological Interactions (2025), pp. 111471-111471
Closed Access
The Role of Bile Acids in Cardiovascular Diseases: from Mechanisms to Clinical Implications
Shuwen Zhang, Junteng Zhou, Wenchao Wu, et al.
Aging and Disease (2022)
Open Access | Times Cited: 25
Update on the development of TGR5 agonists for human diseases
Wangrui Jin, Mingyue Zheng, Yihua Chen, et al.
European Journal of Medicinal Chemistry (2024) Vol. 271, pp. 116462-116462
Closed Access | Times Cited: 4
Different types of bile acids exhibit opposite regulatory effects on lipid metabolism in finishing pigs through bile acid receptors
Yaolian Hu, Ni Sang, Aimin Wu, et al.
Animal nutrition (2025) Vol. 21, pp. 25-36
Open Access
Computational Insights into the Interactions of Farnesoid X Receptor with Fargesone A, a Natural Product from Magnolia fargesii
Li Zhang, Yaqiong Chen, Weihua Li
Chemical Research in Chinese Universities (2025)
Closed Access
FXR agonists INT‐787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet‐induced ob/ob mouse model of NASH
Laura Giuseppina Di Pasqua, Marta Cagna, G. Palladini, et al.
Liver International (2023) Vol. 44, Iss. 1, pp. 214-227
Open Access | Times Cited: 11
Patented Farnesoid X receptor modulators: a review (2019 – present)
Antimo Gioiello, Emiliano Rosatelli, Bruno Cerra
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 7, pp. 547-564
Closed Access | Times Cited: 3
Bile Acids and Biliary Fibrosis
Sayed Obaidullah Aseem, Phillip B. Hylemon, Huiping Zhou
Cells (2023) Vol. 12, Iss. 5, pp. 792-792
Open Access | Times Cited: 9
Discovery of HPG1860, a Structurally Novel Nonbile Acid FXR Agonist Currently in Clinical Development for the Treatment of Nonalcoholic Steatohepatitis
Cheng Mo, Xiaoqing Xu, Pan Zhang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 14, pp. 9363-9375
Closed Access | Times Cited: 9
Dose Prediction and Pharmacokinetic Simulation of XZP-5610, a Small Molecule for NASH Therapy, Using Allometric Scaling and Physiologically Based Pharmacokinetic Models
Lei Zhang, Feifei Feng, Xiaohan Wang, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 369-369
Open Access | Times Cited: 3
Microbial Metabolites as Ligands to Xenobiotic Receptors: Chemical Mimicry as Potential Drugs of the Future
Zdeněk Dvořák, Hao Li, Sridhar Mani
Drug Metabolism and Disposition (2022) Vol. 51, Iss. 2, pp. 219-227
Open Access | Times Cited: 13
Role of FXR in the development of NAFLD and intervention strategies of small molecules
Jiachan Long, Yuanhang Xu, Xuerong Zhang, et al.
Archives of Biochemistry and Biophysics (2024) Vol. 757, pp. 110024-110024
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top